融捷健康(300247) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥94,523,466.14, a decrease of 4.88% compared to the same period last year[6]. - Net profit attributable to shareholders decreased by 82.70% to ¥3,713,105.90, while the net profit excluding non-recurring items was ¥4,092,591.56, down 4.57%[6]. - The company reported a net loss of ¥1,214,805,714.07 as of September 30, 2022, compared to a loss of ¥1,352,972,886.63 at the beginning of the year, indicating an improvement in financial performance[19]. - Total operating revenue for the current period is $330.66 million, down from $367.79 million in the previous period, representing a decrease of approximately 10.1%[21]. - Operating profit increased significantly to $154.73 million from $42.04 million, marking an increase of approximately 268.5%[22]. - Net profit for the current period reached $146.23 million, compared to $36.55 million in the previous period, reflecting an increase of about 300.5%[22]. - Basic and diluted earnings per share improved to $0.1718 from $0.0376, an increase of approximately 356.4%[23]. - The total comprehensive income for the current period was $191.42 million, up from $33.49 million, an increase of approximately 471.5%[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,200,763,730.47, representing a 17.47% increase from the previous year[6]. - The total liabilities decreased from ¥161,064,333.37 to ¥148,204,500.59, a reduction of approximately 7.9%[19]. - The total assets increased from ¥1,022,175,500.47 to ¥1,200,763,730.47, reflecting a growth of about 17.5%[19]. - Total current assets increased from ¥501,441,905.33 at the beginning of the year to ¥776,545,111.36, representing a growth of about 54.7%[18]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥54,436,363.18, a 826.89% increase in outflow compared to the previous period[12]. - Cash flow from operating activities showed a net outflow of $54.44 million, worsening from a net outflow of $5.87 million in the previous period[24]. - Cash flow from investing activities resulted in a net outflow of $13.88 million, compared to a net outflow of $67.49 million previously, indicating an improvement[25]. - The company's cash and cash equivalents decreased by 76.26% to ¥21,678,949.24, attributed to reduced cash receipts from product sales[9]. - The cash and cash equivalents at the end of the period decreased to $21.68 million from $85.99 million, a decline of about 74.7%[25]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,590[14]. - The largest shareholder, Rongjie Investment Holding Group Co., Ltd., holds 14.54% of shares, totaling 116,912,302 shares[15]. - The company has no preferred shareholders as of the reporting date[16]. Inventory and Expenses - The company’s inventory increased by 40.49% to ¥209,557,516.71, driven by product purchases by its U.S. subsidiary[9]. - The company’s financial expenses increased significantly, showing a decrease of 1242.54% to -¥11,406,672.37, influenced by currency exchange rate fluctuations[11]. - The company’s deferred income decreased by 92.80% to ¥9,447.96, reflecting the recognition of income during the reporting period[10]. - The company's inventory increased from ¥149,163,353.47 to ¥209,557,516.71, an increase of approximately 40.5%[18]. - Total operating costs decreased to $317.87 million from $358.50 million, a reduction of about 11.4%[21]. Investment Income - The company reported a significant increase in investment income of 1393.25%, amounting to ¥132,698,822.50, primarily due to the sale of equity in Zhongsheng Suoyuan[11]. - The company reported a significant increase in investment income to $132.70 million from $8.89 million, representing a growth of approximately 1,392.2%[22].